KR101647549B1 - 고콜레스테롤혈증의 치료를 위한 방법 - Google Patents

고콜레스테롤혈증의 치료를 위한 방법 Download PDF

Info

Publication number
KR101647549B1
KR101647549B1 KR1020140070179A KR20140070179A KR101647549B1 KR 101647549 B1 KR101647549 B1 KR 101647549B1 KR 1020140070179 A KR1020140070179 A KR 1020140070179A KR 20140070179 A KR20140070179 A KR 20140070179A KR 101647549 B1 KR101647549 B1 KR 101647549B1
Authority
KR
South Korea
Prior art keywords
mammal
density lipoprotein
calbene
hypercholesterolemia
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020140070179A
Other languages
English (en)
Korean (ko)
Other versions
KR20150122552A (ko
Inventor
무하메드 마제에드
칼야남 나가브허즈하남
안주 마제에드
사랑 바니
안잘리 판데이
Original Assignee
무하메드 마제에드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 무하메드 마제에드 filed Critical 무하메드 마제에드
Publication of KR20150122552A publication Critical patent/KR20150122552A/ko
Application granted granted Critical
Publication of KR101647549B1 publication Critical patent/KR101647549B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/25—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020140070179A 2014-04-23 2014-06-10 고콜레스테롤혈증의 치료를 위한 방법 Expired - Fee Related KR101647549B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/259,404 2014-04-23
US14/259,404 US9668999B2 (en) 2014-04-23 2014-04-23 Method for the treatment of hypercholesterolemia

Publications (2)

Publication Number Publication Date
KR20150122552A KR20150122552A (ko) 2015-11-02
KR101647549B1 true KR101647549B1 (ko) 2016-08-10

Family

ID=50828681

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020140070179A Expired - Fee Related KR101647549B1 (ko) 2014-04-23 2014-06-10 고콜레스테롤혈증의 치료를 위한 방법

Country Status (11)

Country Link
US (2) US9668999B2 (enExample)
EP (1) EP2937084B1 (enExample)
JP (1) JP6263707B2 (enExample)
KR (1) KR101647549B1 (enExample)
AU (1) AU2014202312B2 (enExample)
CA (2) CA2850999C (enExample)
EA (1) EA027148B1 (enExample)
MY (1) MY170067A (enExample)
PH (1) PH12014000244A1 (enExample)
PL (1) PL2937084T3 (enExample)
TW (1) TWI622394B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201503805XA (en) * 2015-04-19 2016-11-29 Sabinsa Corp Calebin A For Hepatic Steatosis
US9539232B1 (en) * 2016-08-04 2017-01-10 Muhammed Majeed Calebin A for osteoporosis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001030335A2 (en) 1999-10-22 2001-05-03 The Board Of Trustees Of The University Of Illinois Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease
WO2013109241A1 (en) 2011-01-10 2013-07-25 Muhammed Majeed Anti-obesity potential of calebin a

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1060352C (zh) * 1996-02-08 2001-01-10 袁克兴 降脂药及其制备方法
US6811786B1 (en) * 1999-04-01 2004-11-02 Ganeden Biotech, Inc. Methods for reducing cholesterol using Bacillus coagulans spores, systems and compositions
US20020012733A1 (en) 2000-04-12 2002-01-31 The Procter & Gamble Company Compositions for reducing hypercholesterolemia and controlling of postprandial blood glucose and insulin levels
JP2005232059A (ja) * 2004-02-18 2005-09-02 Iichiro Shimomura 低アディポネクチン血症予防・治療剤
JP4834824B2 (ja) * 2004-07-08 2011-12-14 独立行政法人産業技術総合研究所 アディポネクチン産生増強剤
JP2010018522A (ja) * 2007-03-23 2010-01-28 Hiroshima Univ アディポネクチン産生促進剤
JP5294165B2 (ja) * 2007-03-23 2013-09-18 ナガセケムテックス株式会社 アディポネクチン上昇剤
CN101301455A (zh) * 2008-07-01 2008-11-12 崔井朝 一种治疗高脂血症的中药复方姜黄固体分散体
JP2011063543A (ja) * 2009-09-17 2011-03-31 Kao Corp アディポネクチン増加剤

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001030335A2 (en) 1999-10-22 2001-05-03 The Board Of Trustees Of The University Of Illinois Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease
WO2013109241A1 (en) 2011-01-10 2013-07-25 Muhammed Majeed Anti-obesity potential of calebin a

Also Published As

Publication number Publication date
KR20150122552A (ko) 2015-11-02
US9610273B2 (en) 2017-04-04
CA2963383C (en) 2018-12-04
NZ624269A (en) 2014-12-24
TW201540295A (zh) 2015-11-01
MY170067A (en) 2019-07-03
CA2850999A1 (en) 2015-10-23
PH12014000244B1 (en) 2016-08-08
EA201491545A1 (ru) 2015-10-30
EP2937084A1 (en) 2015-10-28
JP2015209424A (ja) 2015-11-24
US9668999B2 (en) 2017-06-06
TWI622394B (zh) 2018-05-01
JP6263707B2 (ja) 2018-01-24
CA2963383A1 (en) 2015-10-23
AU2014202312B2 (en) 2018-02-22
CA2850999C (en) 2018-04-03
EA027148B1 (ru) 2017-06-30
PH12014000244A1 (en) 2016-08-08
AU2014202312A1 (en) 2015-11-12
US20150306060A1 (en) 2015-10-29
PL2937084T3 (pl) 2017-05-31
US20150306059A1 (en) 2015-10-29
EP2937084B1 (en) 2016-11-30
HK1210590A1 (en) 2016-04-29

Similar Documents

Publication Publication Date Title
Grandhaye et al. Microbiota changes due to grape seed extract diet improved intestinal homeostasis and decreased fatness in parental broiler hens
Brosius III et al. New targets for treatment of diabetic nephropathy: what we have learned from animal models
Angwech et al. Efficacy of in ovo delivered prebiotics on growth performance, meat quality and gut health of kuroiler chickens in the face of a natural coccidiosis challenge
Zhang et al. Cordycepin (3′-deoxyadenosine) down-regulates the proinflammatory cytokines in inflammation-induced osteoporosis model
CN103709157A (zh) 一种多核分子化合物、其制备方法及用途
Tomaszewska et al. The effect of tannic acid on bone mechanical and geometric properties, bone density, and trabecular histomorphometry as well as the morphology of articular and growth cartilages in rats co-exposed to cadmium and lead is dose dependent
KR101647549B1 (ko) 고콜레스테롤혈증의 치료를 위한 방법
Chen et al. Exogenous expression of an alternative splicing variant of myostatin prompts leg muscle fiber hyperplasia in Japanese quail
JIANG Effect of cholinesterase inhibitor galanthamine on circulating tumor necrosis factor alpha in rats with lipopolysaccharide-induced peritonitis
Pereda et al. Mice lacking chromogranins exhibit increased aggressive and depression-like behaviour
Suginohara et al. Ninjin’yoeito suppressed the onset of arthritis, pain, and muscle atrophy in rheumatoid arthritis model mice
El Sebaei et al. Biochemical and molecular investigation of oxidative stress associated with urolithiasis induced by increased dietary calcium or protein in chickens
Hesse et al. Tegaserod Stimulates 5-HT4 Serotonin Receptors in the Isolated Human Atrium
Tomaszewska et al. The protective role of alpha-ketoglutaric acid on the growth and bone development of experimentally induced perinatal growth-retarded piglets
Kemppinen et al. Impact of aspen furniture and restricted feeding on activity, blood pressure, heart rate and faecal corticosterone and immunoglobulin A excretion in rats (Rattus norvegicus) housed in individually ventilated cages
Muñoz-García et al. Effects of Dietary Oleacein Treatment on Endothelial Dysfunction and Lupus Nephritis in Balb/C Pristane-Induced Mice
NZ624269B (en) Method for the treatment of hypercholesterolemia
HK1210590B (en) Method for the treatment of hypercholesterolemia
CN116942818B (zh) 以brd7为靶点在制备肥胖相关精神疾病药物中的应用
AL-Khafaji Investigation of some Biochemical and histopathological changes in liver and kidney of diet induced obesity in male albino mice treated with rosuvastatin
Al-Hasnawi et al. Effect of aloe vera extract on some parameter complete blood count and liver functions induced by azathioprine in changes male rats
Wei et al. Caloric restriction can ameliorate postoperative cognitive dysfunction by upregulating the expression of Sirt1, MeCP2 and BDNF in the hippocampal CA1 region of aged C57BL/6 mice
Desdín-Micó et al. Immunometabolic T cell failure induces multimorbidity and aging
Mousa et al. High density lipoprotein (HDL) modulation targets
Emeto et al. Urocortin 2 inhibits human aortic smooth muscle cell proliferation via corticotrophin releasing hormone receptor-2 in abdominal aortic aneurysm

Legal Events

Date Code Title Description
A201 Request for examination
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20190625

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20220805

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20220805